Aurinia Pharmaceuticals
AUPH
186 hedge funds and large institutions have $553M invested in Aurinia Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 30 closing their positions.
148% more capital invested
Capital invested by funds: $223M → $553M (+$330M)
50% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 46
40% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $21.7M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.88% less ownership
Funds ownership: 36.31% → 35.43% (-0.88%)
3% less funds holding
Funds holding: 192 → 186 (-6)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.51M |
| 2 |
Goldman Sachs
New York
|
+$4.57M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.51M |
| 4 |
Morgan Stanley
New York
|
+$3.4M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11.7M |
| 2 |
AC
Armistice Capital
New York
|
-$7.29M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$5.57M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.69M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$2.42M |
AUPH Hedge Fund Activity: Q1 2023 in Review
186 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2023, worth a combined $553M — up 148% from $223M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of AUPH and 27 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 69 added.
The largest buyer was Balyasny Asset Management, adding an estimated $7.51M. The largest seller was Citadel Advisors, cutting an estimated $11.7M.
- 186 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2023, down from 192 in Q4 2022.
- Funds reported $553M of Aurinia Pharmaceuticals stock for Q1 2023, up 148% quarter-over-quarter.
- 27 funds opened new Aurinia Pharmaceuticals positions in Q1 2023 and 30 closed out, a net change of -3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2023 was Balyasny Asset Management, an estimated $7.51M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2023 was Citadel Advisors, an estimated $11.7M sold.
Based on aggregated 13F filings for Q1 2023.